



## PRESS RELEASE

### The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs

Leiden, June 22<sup>nd</sup> 2009

**to-BBB, the Dutch brain drug delivery company, and Dr. Olaf van Tellingen from the Department of Clinical Chemistry of The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) will collaborate on the development of a potential new therapy for Brain Tumors.**

Brain Tumors are highly aggressive and most often fatal cancers that affect up to 200,000 patients annually in the United States and similar numbers in Europe. Chemotherapeutic treatment options for primary and metastatic brain cancer patients are limited and overall prognoses are dismal. To a large extent this is due to the neuroprotective role of the blood-brain barrier (BBB), limiting the safe delivery of many anti-cancer drugs to their disease target in the brain.

The research group of Dr. van Tellingen has developed a series of advanced experimental models to address key topics in the development of new therapies for Brain Tumors, including their transport across the blood-brain barrier.

to-BBB's G-Technology™ is designed for safe brain delivery of different classes of drugs by formulating these drugs into proprietary glutathione coated stealth liposomes. The G-Technology™ has shown proof of concept in several disease models, based on which the research group of Dr. van Tellingen and to-BBB will join forces to develop brain-targeted liposomes with encapsulated anti-cancer drugs.

Pieter Gaillard, CSO of to-BBB, indicates the importance of this collaboration: "We are looking forward to combine to-BBB's brain delivery technology with Dr. van Tellingen's capabilities in the area of Brain Tumors to be able to ultimately improve the lives of patients with this devastating disease."

#### **About to-BBB**

to-BBB is a Dutch biotechnology company in the field of drug delivery to the brain which uses its platform technologies to synergize with established and marketed drugs. to-BBB's vision is that the treatment of currently unserved brain diseases will be best achieved by targeting to endogenous blood-to-brain uptake systems for the delivery of drugs. The company is developing treatments for devastating brain disorders by combining existing drugs with proprietary brain delivery technologies.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

#### **About NKI-AVL**

The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), combines a scientific research laboratory with a specialized clinic and is widely regarded as a world-class institute in its field. Since its foundation in 1913, the primary objective of the NKI-AVL has been to make a substantial contribution to combating cancer through a unique interaction of scientific research and clinical application, supported by strong training.

## Contact to-BBB

*Willem van Weperen*  
Chief Executive Officer

Phone: +31 71 3322252  
Mobile: +31 634 054812  
E-mail: vanweperen@toBBB.com

**to-BBB technologies BV**  
Niels Bohrweg 11, 2333 CA Leiden  
BioScience Park Leiden  
Bio Partner Center II  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)

*Pieter Gaillard, PhD*  
Chief Scientific Officer

Phone: +31 71 3322251  
Mobile: +31 621 525000  
E-mail: gaillard@toBBB.com

**to-BBB technologies BV**  
Niels Bohrweg 11, 2333 CA Leiden  
BioScience Park Leiden  
Bio Partner Center II  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)

## Contact NKI-AVL

*Olaf van Tellingen, PhD*  
Research Scientist

Phone: +31 20 5122792  
E-mail: o.v.tellingen@nki.nl

**The Netherlands Cancer Institute**  
Room C1.005  
Plesmanlaan 121, 1066 CX Amstrdam  
The Netherlands  
[www.nki.nl](http://www.nki.nl)